We design custom communications programs for all stages of growth.

Bioscribe’s integrated approach helps companies implement the right mix of communications programs at the right time to meet corporate goals and objectives. Our service model is flexible to support early-stage companies and to scale with them over time.

services-icon Corporate Communications

Messaging and positioning. Product and development milestones. Branding. Website development. Financing milestones and exit communications. Internal communications. Crisis communications.

services-icon Media Strategy and Public Relations

Press releases. Q&A development. Media pitching and story development. Media monitoring. Media training and interview prep.

services-icon Social Media

Social media strategy and profile management. Blog management. Video scripting and production. Infographics. Targeted and paid campaigns. Monitoring and analytics.

services-icon Content Development

Thought leadership content. Bylined articles. White papers. Case studies. Customer profiles. Marketing collateral. Tech notes and app notes. Technology backgrounders. Patient/professional education materials. Editorial calendar planning.

services-icon Events

Launch and press events. Scientific, medical, and industry conference coverage. Speaking opportunities. Presentation development. Ribbon-cutting ceremonies and open-house events. Patient/advocacy events.

services-icon Advocacy

Professional and patient alliance cultivation. KOL advisory panels. Member communications/outreach. Collaboration and partnership opportunities. Celebrity spokesperson campaigns.

services-icon Marketing Communications

Product launches. Sales collateral. Customer communications. Lead generation and nurturing campaigns. Award submissions. Advertising. Targeted campaigns.

Our clients are making headlines.

Pattern Bioscience raises $28.7M Series C for faster, more efficient antibiotic resistance test
Pattern Bioscience raises $28.7M Series C for faster, more efficient antibiotic resistance test
Learn More news-arrow
Pattern Bioscience raises $28.7M Series C for faster, more efficient antibiotic resistance test
Pattern Bioscience raises $28.7M Series C for faster, more efficient antibiotic resistance test
The Evolution of Spatial Biology with Ken Bloom, MD
This Desktop Machine Is About To Transform The Decades-Old DNA Synthesis Industry
Kinnate Biopharma touts early efficacy in pan-RAF program
Researchers dig into cancer niches
How to Choose the Right Cancer Knowledge Base for Variant Interpretation
As CML Outcomes Improve, Demand Rises for BCR::ABL1 Testing
Fierce Medtech’s 2022 Fierce 15
A Recipe For Start-Up Success With A Platform Technology
Spatial Biology Allows Drug Discovery Scientists to Ask New Questions
Trendspotting: Hybrid and Decentralized Clinical Trials, Patient-Centricity, and Increased Remote Patient Monitoring in 2023
Enabling the Synthetic Biology Revolution
Trendspotting: What’s Coming for Bio-IT in 2023
Validated Oncogenic Drivers: An Important Source to Expand Targeted Therapy Access
2022 Top 10 Innovations
This Company Just Raised $71 Million To See The Forest For The Trees Within A Patient’s Cells
Tasso earns FDA clearance for its home blood collection device for telehealth tests
Purigen Biosystems Inks Distribution Deal for Nucleic Acid Extraction System in France
Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin
For Drug Discovery Research, Laboratory Automation Needs to Be Flexible
New kid on the block: Roger Perlmutter’s biotech signs on as anchor tenant to new Bay Area campus
The AI 50
Tech advances can reduce cost of producing gene-edited crops by tenfold: Agricultural biotech firm
Blackstone Growth Leads $200 Million Investment in DNAnexus
The Ultimate Vision for Rare Disease
Tasso Raises $100 Million in Series B Funding
Eikon Therapeutics Rakes In $518M
Previous Next

We are passionate about promoting the value of life science innovations.

Bioscribe has worked at the intersection of biology and information technology since our founding in 1997. Over that time, we’ve provided expert communications counsel to companies that are advancing biotherapeutics, omics technologies, molecular diagnostics, AI and bioinformatics, lab automation, molecular and synthetic biology, and other healthcare and bioindustrial applications that are helping to create a better world and a healthier future.

From pre-commercial stages to product launch and exits, Bioscribe creates integrated, scalable, and multi-channel strategic programs for corporate and marketing communications. We are skilled at helping companies create the right mix of programs for their development stage and budgets, and at extending the reach of our communications campaigns to maximize return on investment.

Our team members have an average of 20+ years of experience and represent a mix of relevant backgrounds in the life sciences — from former industry and business journalists and scientists to long-time healthcare communicators and brand builders who have led teams in agencies and in-house. This mix allows us to bring a broader perspective and rich spectrum of ideas, insights, and creativity to our work.

Contact us to learn more about how we can make a difference for you.

Our clients are life science innovators helping to create a healthier future.

All Biopharma Life science technologies Diagnostics

We are an all-senior team with 20+ years experience on average.

Nicole Litchfield
Colin Sanford
Senior Consultants
Andrew Noble
Anthony Petrucci
Chris Lieu
Ellen Leventry
Emily Barker-Clement
Joan Kureczka
Mary Bowen
Meredith Salisbury
Michele Parisi
Nancie Steinberg
Stacey Shackford
Steve Thompson
Susan Sharpe
Suzanne Howard
Tim Ingersoll
Uduak Thomas
Wendy Diller

Bioscribe Datapoints

‘97 Year established
200 Companies served
20 Average team experience
110 Effort for every client

Follow us for the latest updates.


We’d love to talk to you if you need help telling your story.

This field is for validation purposes and should be left unchanged.